AstraZeneca DTx. Virgin Pulse takes on Omada.

Issue 034. Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 56 percent open rate. Here's what's happening this week:

Healthcare investor and founder of NaviMed Capital, Bijan Salehizadeh, took VC-dabbling hospital executives behind the woodshed. In a well-liked Twitter thread, he explained why health systems' VC arms are shutting down. He noted (without naming names) that four high-profile non-profit health systems investment arms pulled the plug in recent months. (New York-Presbyterian, Inova and... who and who?) Tweets here.
One more Twitter thread worth a skim: Atul Gawande, who currently heads up Haven, tweeted some thoughts on the long-awaited, just-published RCT that revisits the concept of hot-spotting in population health. Gawande made the concept famous in a New Yorker article nine years ago. The RCT showed the

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

AstraZeneca DTx. Virgin Pulse takes on Omada.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.